Biodexa Pharmaceuticals PLC ADR美股招股说明书(2025-06-02版)

4,349,102,800 Ordinary Shares Representing 434,901 American Depositary SharesThis prospectus supplement No. 3 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our shareholders identified in the Prospectus of up to an aggregate of 4,349,102,800 of our ordinary shares, nominal value £0.00005 pershare, represented by 434,901 American Depositary Shares (the “Depositary Shares”). This Prospectus Supplement is being filed in order to incorporate into and include in the Prospectus the information contained in our attached Form 6-K, filed with the Securities and Exchange Commission on May 30, 2025.This Prospectus Supplement should be read in conjunction with the Prospectus and is qualified by reference to the Prospectusexcept to the extent that the information in this Prospectus Supplement supersedes the information contained therein. Investing in our securities involves risks. See “Risk Factors” beginning on page 9 of the Prospectus and in the Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of ______________________________ The date of this Prospectus Supplement is June 2, 2025. Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIESEXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number:001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom(Address of principal executive office)Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. behalf by the undersigned, thereunto duly authorized.Biodexa Pharmaceuticals PLC(Registrant) May 30, 2025 Shareholder Update Financial positionAs of May 29, 2025, the Company had access to the following cash resources: $ millionsCash at bank5.7Cash in escrow for eRapa Phase 3 program4.410.1Undrawn CPRIT grant for eRapa Phase 3 program11.9 projections, the Company has sufficient working capital to fund operations into the first quarter of 2026.Issued shares, total voting rights, market capitalizationAs of May 29, 2025, there were 50,506,308,922 ordinary shares, equivalent to 5,050,630 American Depositary Shares (ADSs),outstanding. The Company holds zero shares in treasury and therefore the number of voting rights is the same as the number ofordinary shares outstanding.